Differential diagnosis of cervical intraepithelial neoplasia of varying severity via quantitative assessment of anti-oncogenic microRNA expression


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Subjects and methods. The investigation enrolled 101 women aged 18 to 49years (mean age, 32.7±0.5years) who were divided into 4 groups: 1) 30 patients without cervical lesions; 2) 32 with low-grade squamous intraepithelial lesion (LSIL); 3) 26 with high-grade squamous intraepithelial lesions (HSIL); 4) 13 with cancer of cervix uteri CCU). Clinical diagnosis was established by cytological and histological studies and extended colposcopy. Quantitative real-time PCR was used to test for human papillomavirus and to measure miRNA expression lesions. Results. The synthesis of anti-oncogenic microRNAs, such as mir-143, mir-145, and mir-199, considerably reduced in the epithelium of the cervix uteri in its neoplastic lesions. At the same time, the expression of mir-143 and mir-145 was reduced in proportion to the severity of a lesion - the minimum expression level was observed in CCU. The expression rates of both separate microRNAs and the total expression rate of two (mir-143 and mir-145) or three (mir-143, mir-145, and mir-199) microRNAs in the cervical scrapings allowed differentiation of women with low-grade and high-grade intraepithelial hyperplasia and those with CCU. Conclusion. This study permits the expression level of miRNAs, such as mir-143, mir-145, and mir-199, along with traditional methods, to be considered as an informative molecular marker to predict the extent of involvement of the cervical epithelium in neoplastic cervical diseases.

Full Text

Restricted Access

About the authors

Vitaliy Nikolaevich Karnaukhov

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: v_kamauhov@oparina4.ru
Junior Researcher, Laboratory of Molecular Genetic Methods

Leonid Zakievich Faizullin

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: l_faizullin@oparina4.ru
Cand. Sc. (Biology), Leading Researcher, Laboratory of Molecular Genetic Methods

Niso Mirzoevna Nazarova

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: grab2@yandex.ru
MD, PhD, Senior Researcher

Guranda Merabovna Mzarelua

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: mzareluag@mail.ru
PhD student

Guldana Raufovna Bairamova

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: g_bairamova@oparina4.ru
doctor of medical sciences, head of the clinical work of the scientific and polyclinic department

Victoria Fedorovna Chernova

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

PhD student

Alexey Leonidovich Faizullin

I.M. Sechenov First Moscow State Medical University

Email: a.iiepcuk@gmail.com
a student of the 6th year; Center for Innovative Educational Programs

Andrey Vladimirovich Kozachenko

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: a_kozachenko@oparina4.ru
leading research assistant of the gynecological department

Dmitriy Yurievich Trofimov

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: d_trofimov@oparina4.ru
Doctor of Biological Sciences, Head of the Laboratory of Molecular Genetic Methods

Vera Nikolaevna Prilepskaya

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: VPrilepskaya@mail.ru
MD, PhD, Professor, Deputy Director for Science

Gennady Tikhonovich Sukhikh

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: g_sukhikh@oparina4.ru
Doctor of Medical Sciences, Academician of the Russian Academy of Sciences, Director

References

  1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011; 61(2): 69-90.
  2. Давыдов М.И., Аксель Е.М., ред. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. М.: Издательская группа РОНЦ; 2014: 47. [Davydov M.I., Aksel E.M., ed. Statistics of malignant neoplasms in Russia and the CIS countries in 2012. Moscow: Publishing group RONTS; 2014: 47. (in Russian)]
  3. Seoud M., Tjalma W.A., Ronsse V. Cervical adenocarcinoma: moving towards better prevention. Vaccine. 2011; 29(49): 9148-58.
  4. Knoff J., Yang B., Hung C.F., Wu T.C. Cervical cancer: development of targeted therapies beyond molecular pathogenesis. Curr. Obstet. Gynecol. Rep. 2014; 3(1): 18-32.
  5. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990; 63(6): 1129-36.
  6. Roman A., Munger K. The papillomavirus E7 proteins. Virology. 2013; 445(1-2): 138-68.
  7. Stahlhut C., Slack F.J. MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications. Genome Med. 2013; 5(12): 111.
  8. Frixa T., Donzelli S., Blandino G. Oncogenic microRNAs: key players in malignant transformation. Cancers (Basel). 2015; 7(4): 2466-85.
  9. Wang F., Li B., Xie X. The roles and clinical significance of microRNAs in cervical cancer. Histol. Histopathol. 2016; 31(2): 131-9.
  10. Galamb Á., Benczik M., Zinner B., Vigh E., Baghy K., Jeney C. et al. Dysregulation of microRNA expression in human cervical preneoplastic and neoplastic lesions. Pathol. Oncol. Res. 2015; 21(3): 503-8.
  11. Файзуллин Л.З., Карнаухов В.Н., Мзарелуа Г.М., Чернова В.Ф. Экспрессия микроРНК при цервикальной интраэпителиальной неоплазии и раке шейки матки. Акушерство и гинекология. 2015; 9: 27-32. [Faizullin L.Z., Karnaukhov V.N., Mzarelua G.M., Chernova V.F. MicroRNA expression in cervical intraepithelial neoplasia and cancer of the cervix uteri. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2015; (9): 27-32. (in Russian)]
  12. Nassirpour R., Mehta P.P., Yin M.J. miR-122 regulates tumorigenesis in hepatocellular carcinoma by targeting AKT3. PLoS One. 2013; 8: e79655.
  13. Ergün S., Ulasli M., Igci Y.Z., Igci M., Kirkbes S., Borazan E. et al. The association of the expression of miR-122-5p and its target ADAM10 with human breast cancer. Mol. Biol. Rep. 2015; 42(2): 497-505.
  14. Kent O.A., McCall M.N., Cornish T.C., Halushka M.K. Lessons from miR-143/145: the importance of cell-type localization of miRNAs. Nucleic Acids Res. 2014; 42(12): 7528-38.
  15. Akao Y., Nakagawa Y., Naoe T. MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol. Rep. 2006; 16(4): 845-50.
  16. Pekow J., Meckel K., Dougherty U., Butun E., Mustafi R., Lim J. et al. Tumor suppressors miRNA-143 and miR-145 and predicted target proteins API5, ERK5, KRAS, and IRS-1 are differentially expressed in proximal and distal colon. Am. J. Physiol. Gastrointest. Liver Physiol. 2015; 308(3): G179-87.
  17. Sachdeva M., Mo Y.Y. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 2010; 70(1): 378-87.
  18. Filipowicz W., Grosshans H. The liver-specific microRNA miR-122: biology and therapeutic potential. Prog. Drug Res. 2011; 67: 221-38.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies